IGF-1 LR3 vs Mecasermin
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Long R3 IGF-1, LR3
IGF-1 LR3 is a modified version of insulin-like growth factor 1, engineered to last far longer in the body than the natural hormone. It is popular in physique circles and it is worth being blunt about the evidence: there are effectively no human clinical trials of this specific analog. Everything below the mechanism section is preclinical work, laboratory use, or community reporting.
Also: Increlex, rhIGF-1
Mecasermin is recombinant human IGF-1, identical to the 70-amino-acid hormone your liver makes in response to growth hormone. Sold as Increlex, it was FDA approved in 2005 for a narrow group: children with severe primary IGF-1 deficiency (mostly Laron syndrome) or a growth hormone gene deletion with antibodies against GH. In those kids it is the only thing that works, because GH cannot do its job. It is not a GH substitute, and its real risks (low blood sugar, tonsil overgrowth, cancer warnings) are why it stays a specialist drug.
Key Comparison Insights
- Mecasermin is FDA approved, while IGF-1 LR3 remains in research stages.
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
- Mecasermin has stronger research evidence (FDA Approved) compared to IGF-1 LR3 (Preclinical).
Detailed Comparison
| Attribute | IGF-1 LR3 | Mecasermin |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Natural IGF-1 is almost entirely bound up by IGF binding proteins in circulation, which controls how much is active and gives it a half-life measured in minutes. LR3 makes two changes: an arginine substitution at position 3, and a 13-amino-acid extension on the N-terminus. Together these dramatically reduce binding-protein affinity, so far more of the molecule stays free and active, extending the functional half-life to something on the order of a day rather than minutes. Once free, it activates the IGF-1 receptor, driving protein synthesis, satellite cell activation and cell proliferation in muscle. That same lack of binding-protein regulation is the reason for caution: binding proteins are a control mechanism, and removing the control is the point of the drug and also its main risk. | Normally, growth hormone binds receptors in the liver and other tissues and triggers IGF-1 production. IGF-1 then activates the type 1 IGF receptor on bone, cartilage and other cells, driving growth. In Laron syndrome the GH receptor is broken, so GH levels are high but IGF-1 stays low. Mecasermin skips the broken step and supplies IGF-1 directly. Because the IGF-1 receptor is a close relative of the insulin receptor, and because IGF-1 can also bind the insulin receptor at higher levels, it lowers blood sugar. That is why the label says to give it within about 20 minutes of a meal or snack. It is mostly carried by IGF binding protein 3 in blood, and its clearance depends on IGFBP-3 levels; the label reports a mean terminal half-life of about 5.8 hours in children with severe primary IGF-1 deficiency. |
| Common Dosing | 20-50 mcg daily Once daily | 0.04-0.08 mg/kg twice daily to start Twice daily |
| Administration | Subcutaneous injection. Because of the hypoglycemia risk, timing relative to carbohydrate intake is the main practical consideration reported. | Subcutaneous injection, rotating sites, within about 20 minutes before or after a meal or snack |
| Typical Duration | Community cycles are typically reported as 4-6 weeks, on the reasoning that receptor downregulation follows longer use | Long-term, until growth plates close (closed epiphyses are a contraindication) |
| Best Time to Take | With or near a carbohydrate-containing meal | Shortly before or after a meal or snack, twice daily |
Possible Side Effects May vary by individual |
|
|
| Research Summary | IGF-1 LR3 was developed as a cell culture reagent, and that remains its principal legitimate use: it is sold to laboratories to promote cell growth in bioreactors. There are no published randomized human trials of IGF-1 LR3 for muscle growth, body composition or performance. The animal and in vitro work does show what you would expect, increased protein synthesis and muscle cell proliferation, and there is a genuine human literature on recombinant IGF-1 (mecasermin) for severe IGF-1 deficiency, but mecasermin is a different molecule with different pharmacokinetics and its trial data should not be read across. The two consistent safety themes in the underlying biology are hypoglycemia, because IGF-1 has meaningful cross-reactivity with the insulin receptor, and the theoretical concern that chronically elevated IGF-1 signalling promotes growth of tissue you did not intend to grow, including existing tumors. | The approval rests on five pooled studies (four open-label, one placebo-controlled) in 71 children with severe primary IGF-1 deficiency, 87% of whom had Laron syndrome. Height velocity rose from 2.8 cm per year before treatment to 8.0 cm per year in year 1, then settled around 4.5 to 5.8 cm per year in later years, still above baseline. Height scores improved but these children stayed very short (mean height SDS went from -6.7 to about -5.2 after 8 years), so it helps rather than normalizes. Hypoglycemia was reported in 42% of children at least once, and tonsillar hypertrophy in 15%. The label carries warnings for hypoglycemic seizures, anaphylaxis, intracranial hypertension, slipped capital femoral epiphysis (added July 2025), scoliosis progression, and postmarketing reports of malignant neoplasms; malignancy is a contraindication. Ownership changed recently: Eton Pharmaceuticals bought Increlex from Ipsen in December 2024 and in 2025 licensed rights outside the US to Esteve. Adult use, anti-aging use, and bodybuilding use are off-label and unsupported by trials. |
Frequently Asked Questions: IGF-1 LR3 vs Mecasermin
What is the difference between IGF-1 LR3 and Mecasermin?
IGF-1 LR3 is a growth hormone peptide that igf-1 lr3 is a modified version of insulin-like growth factor 1, engineered to last far longer in the body than the natural hormone. it is popular in physique circles and it is worth being blunt about the evidence: there are effectively no human clinical trials of this specific analog. everything below the mechanism section is preclinical work, laboratory use, or community reporting. Mecasermin is a growth hormone peptide that mecasermin is recombinant human igf-1, identical to the 70-amino-acid hormone your liver makes in response to growth hormone. sold as increlex, it was fda approved in 2005 for a narrow group: children with severe primary igf-1 deficiency (mostly laron syndrome) or a growth hormone gene deletion with antibodies against gh. in those kids it is the only thing that works, because gh cannot do its job. it is not a gh substitute, and its real risks (low blood sugar, tonsil overgrowth, cancer warnings) are why it stays a specialist drug. The main differences lie in their mechanisms of action and clinical applications.
Which is better, IGF-1 LR3 or Mecasermin?
Neither is universally "better" - the choice depends on your specific goals. IGF-1 LR3 is typically used for growth hormone purposes, while Mecasermin is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can IGF-1 LR3 and Mecasermin be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using IGF-1 LR3 and Mecasermin together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.